NT5E CpG island methylation is a favourable breast cancer biomarker.

When analysing by histological subtype, we confirmed the association of CpG island methylation with lower probability of metastasis in ER negative ( P =0.049, OR=0.21, 95% CI: 0.05–0.83) and in TNBC cases ( P =0.017, OR=0.09, 95% CI: 0.01–0.55) ( Figure 5B ), but in the cohort of 119 ER-positive cases, this association just failed to reach statistical significance ( P =0.08, OR=0.4271, 95% CI: 0.20–1.09) ( Figure 5B ).

also in 203 other papers

A further potential mechanism linking absence of methylation with less favourable outcome after chemotherapy is the highly significant association between absence of NT5E CpG island methylation and mutation in TP53 .

also in 132,142 other papers